Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2014

View Archived Issues

Kinetic analysis of the new PET ligand [11C]Lu-AE-92686

ProteoTech given FDA orphan drug status for AL amyloidosis candidate

RetroSense Therapeutics gene therapy gains FDA orphan drug status for retinitis pigmentosa

RadioMedix and Viewpoint Molecular Targeting receive grant for melanoma theranostics

iBio expands collaboration with Novici Biotech

Bavarian Nordic expands collaboration with Janssen on MVA-BN

GlaxoSmithKline reviews pipeline progress of third quarter 2014

VSV-ZEBOV Ebola vaccine candidate begins phase I study at NIAID

Serum bilirubin: a prognostic marker in primary sclerosing cholangitis

Phase III data from GEMINI trials presented for vedolizumab

First-in-human results presented for radiolabeled antibody [68Ga]ABY-025

Vitae Pharmaceuticals reports phase I results for BI-1181181/VTP-37948

The Walter Reed Army Institute discloses new agents for malaria

Novel GPR120 modulators divulged by Bristol-Myers Squibb

SHIELD 4 phase III data presented for vercirnon in patients with Crohn's disease

Sutro Biopharma and Celgene expand agreement for ADCs in immuno-oncology

U.S. group designs novel agents for depression and Parkinson's disease

Sumitomo Dainippon Pharma discloses novel RIO kinase 2 inhibitors

Bristol-Myers Squibb prepares novel agents for HIV infection

Stellar Biotechnologies agrees to supply KLH for BiovaxID

CTI BioPharma acquires worldwide rights to phase II cancer agent tosedostat

FDA sends CRL to Lundbeck regarding intravenous carbamazepine NDA

FDA approves Baxter's Obizur for acquired hemophilia A

CHMP adopts positive opinion for oxycodone/naloxone in RLS

CHMP recommends expanding approval of enzalutamide

EMA committee backs approval of olaparib in BRCA-mutated ovarian cancer

EMA recommends that Clinuvel's Scenesse be approved for EPP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...